Medically reviewed by Huma Sheikh, MDKey TakeawaysThe medications approved by the Food and Drug Administration (FDA) for ...

Please provide your email address to receive an email when new articles are posted on . Most patients with chorea and antiphospholipid antibody were women, with chorea onset at an average age of 22.8 ...

A case report indicates that valbenazine may be an effective therapy for chorea-ballism associated with tardive dyskinesia. Valbenazine has therapeutic potential to improve chorea-ballism associated ...

SAN DIEGO, Sept. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT ®-HD2 study of INGREZZA ® (valbenazine) ...

SAN DIEGO, March 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) presented data from the KINECT ®-HD study showcasing significant improvements in chorea across body regions ...

Huntington's disease is a genetic neurodegenerative disorder that affects both motor and cognitive function and gradually reduces the independence and quality of life of those affected. One of the ...

Please provide your email address to receive an email when new articles are posted on . The new once-daily tablet strength doses are 30 mg, 36 mg, 42 mg and 48 mg. Symptom improvement in tardive ...

The US Food and Drug Administration (FDA) has approved deutetrabenazine extended-release tablets (Austedo XR, Teva), a new once-daily formulation of the drug for adults with tardive dyskinesia (TD) or ...

Benign hereditary chorea (BHC) is a rare, autosomal dominant neurological disorder characterised by early-onset, non-progressive chorea. Mutations in the NKX2-1 gene, which encodes the thyroid ...

Symptoms of ARF tend to present themselves 1-3 weeks after infection. A high index of suspicion for ARF must be maintained, especially because a single diagnostic tool does not exist. Thomas D. Jones ...